US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 0.485
- -0.017-3.39%
Close Apr 19 16:00 ET
- 0.493
- +0.008+1.59%
Post 17:35 ET
2.82MMarket Cap-4P/E (TTM)
0.503High0.476Low112.98KVolume0.490Open0.502Pre Close55.57KTurnover1.95%Turnover RatioLossP/E (Static)5.81MShares356.00052wk High1.71P/B2.82MFloat Cap0.47052wk Low--Dividend TTM5.81MShs Float5600.000Historical High--Div YieldTTM5.38%Amplitude0.470Historical Low0.491Avg Price1Lot Size
About Transcode Therapeutics Company
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Company Profile
SymbolRNAZ
Company NameTranscode Therapeutics
Listing DateJul 9, 2021
Issue Price4.00
Founded2016
CEOMr. Thomas A. Fitzgerald, M.B.A.
MarketNASDAQ
Employees10
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address6 Liberty Square,Suite 2382
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02109
Phone1-857-837-3099
Company Executives
- Name
- Position
- Salary
- Thomas A. Fitzgerald, M.B.A.
- Interim President, Chief Executive Officer, Director, Vice President, Chief Financial Officer and Principal Accounting Officer
- 560.70K
- Dr. Zdravka Medarova
- Chief Technology Officer
- --
- Dr. Qiyong Peter Liu, PhD
- Vice President, Research and Development and Chief Scientist
- --
- Dr. Philippe P. Calais, PhD
- Executive Chairman of the Board
- 111.54K
- Dr. Magda Marquet, PhD
- Independent Director
- 71.54K
- Dr. Erik Manting, PhD
- Independent Director
- 69.54K
- Dr. Anna Moore, PhD
- Scientific Advisor
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg